Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30081480 | 1.00 | CYP1A2 (0.57) | CYP1A2ALDH1A1KDM4EPOLBNQO2 | |
| SCHEMBL30081476 | 0.86 | NCF1 (0.65) | CYP1A2ALDH1A1KDM4EPOLBNQO2 | |
| SCHEMBL806266 | 0.86 | NCF1 (0.65) | CYP1A2ALDH1A1KDM4EPOLBNQO2 | |
| Iodide SCHEMBL28889538 | 0.84 | NCF1 (0.62) | CYP1A2ALDH1A1KDM4EPOLBNQO2 | |
| Iodomethane SCHEMBL28083726 | 0.82 | NCF1 (0.61) | CYP1A2ALDH1A1KDM4EPOLBNQO2 | |
| SCHEMBL2095030 | 0.82 | CYP1A2 (0.55) | CYP1A2KDM4EPOLBLMNA | |
| SCHEMBL31060199 | 0.81 | — | — | |
| SCHEMBL13737643 | 0.79 | MAPT (0.53) | CYP1A2ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL13737763 | 0.78 | NCF1 (0.51) | CYP1A2ALDH1A1HSD17B10NCF1 | |
| SCHEMBL9193884 | 0.78 | NCF1 (0.56) | CYP1A2ALDH1A1KDM4EPOLBNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223039-A1 | SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223034-A1 | SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| EP-2736885-B1 | QUINOLINE-, QUINOXALINE OR BENZOTHIAZOLE BASED CYSTEINYL LEUKOTRIENE ANTAGONISTS (LTC4) | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-03-25 | — | — | EP | disclosed |
| CN-106083713-B | A kind of chemical synthesis process of quinoline () quinoline -2- benzaldehyde compound | 浙江工业大学 | 2019-07-26 | — | — | CN | disclosed |
| US-10300155-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-1406631-A2 | DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2002100350-A2 | DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON | THE REGENTS OF UNIVERSITY OF MICHIGAN (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | disclosed |
| CN-1054845-C | Quinoline compounds | NOVARTIS AG (CH) | 2000-07-26 | — | — | CN | disclosed |
| EP-0643045-B1 | Quinoline derivatives as leukotriene antagonists | NOVARTIS AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| US-5508408-A | LEUKOTRIENE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
| CN-1105991-A | Quinoline compounds | CIBA GEIGY AG (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0643045-A1 | Quinoline derivatives as leukoriene antagonists | CIBA-GEIGY AG (CH) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | CYP1A2 3639/4885ALDH1A1 4136/4885KDM4E 2731/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP1A2 572/4885ALDH1A1 1739/4885KDM4E 3044/4885 |
| US-10300155-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | CYP1A2 4628/4885ALDH1A1 2333/4885KDM4E 4649/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CYP1A2 2128/4885ALDH1A1 2200/4885KDM4E 61/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | CYP1A2 3639/4885ALDH1A1 4136/4885KDM4E 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.